Vivos Therapeutics
VVOS
28 hedge funds and large institutions have $861K invested in Vivos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 9 closing their positions.
0.03% less ownership
Funds ownership: 0.63% → 0.6% (-0.03%)
7% less funds holding
Funds holding: 30 → 28 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
64% less capital invested
Capital invested by funds: $2.39M → $861K (-$1.53M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$26.5K |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$16.1K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$5.63K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.79K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGI
Godsey & Gibb Inc
Richmond,
Virginia
|
-$47.4K |
| 2 |
Two Sigma Investments
New York
|
-$32.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.9K |
| 4 |
VF
Virtu Financial
New York
|
-$26K |
| 5 |
Renaissance Technologies
New York
|
-$17K |
VVOS Hedge Fund Activity: Q3 2023 in Review
28 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2023, worth a combined $861K — down 64% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VVOS and 7 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $26.5K. The largest seller was Godsey & Gibb Inc, exiting entirely with an estimated $47.4K sold.
- 28 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2023, down from 30 in Q2 2023.
- Funds reported $861K of Vivos Therapeutics stock for Q3 2023, down 64% quarter-over-quarter.
- 7 funds opened new Vivos Therapeutics positions in Q3 2023 and 9 closed out, a net change of -2 holders.
- The largest Vivos Therapeutics buyer in Q3 2023 was HRT Financial, an estimated $26.5K added.
- The largest Vivos Therapeutics seller in Q3 2023 was Godsey & Gibb Inc, an estimated $47.4K sold.
Based on aggregated 13F filings for Q3 2023.